Oslo, 3 March 2021 – Arctic Bioscience is featured in the government initiated Explorer Project. On a mission to make Norway a sustainability pioneer globally, Innovation Norway launched The Explorer – a marketplace promoting green technology. All companies presented have solid ESG footprints and solutions linked to specific Sustainable Development Goals.
“Arctic Bioscience is a forward-thinking, innovative company, and we are committed to sustainability throughout the entire value chain. It is exciting to be a part of Norway’s green transition.”Ole Arne Eiksund, CEO of Arctic Bioscience.
The team has developed technology that allows us to utilize the unique chemical composition of herring roe. This raw material was previously considered waste from herring fillet production. With our proprietary extraction methods, herring roe is now utilized to create high-quality extracts for both nutraceutical products and pharmaceutical development. This leaves a robust ESG footprint we are proud of.
“We are proud of our ESG footprint and pleased to be recognized for the value we create. The Explorer will be an important arena promoting green growth, and we are excited to be a part of it.”Ole Arne Eiksund, CEO of Arctic Bioscience.
In 2020 Arctic Bioscience received the annual Siva-award for promoting green growth. The award was announced by the Minister of Industry and Trade, Iselin Nybø.
Arctic Bioscience uses proprietary technology developed by our in-house science and technology team in Ørsta to manufacture high-quality marine extracts. The extraction technique and production process utilize specialized technology to gently separate the protein and lipid fractions in the herring roe. By using this technology the product fractions are protected from being exposed to unnecessary heating and detrimental amounts of oxygen. Extensive use of high manufacturing temperatures and exposure to oxygen will lead to deterioration of the delicate natural products extracted from the roe, where the complex polar lipid fraction of the roe is particularly susceptible to degradation upon exposure to harsh manufacturing conditions.
The new state-of-the-art manufacturing facility currently being developed in Ørsta will be built around the same manufacturing principles, thus ensuring production of high-quality materials both for nutraceutical and pharmaceutical applications. The factory will have one manufacturing line operating according to cGMP, which allows for in-house API manufacture for the pharmaceutical development of our complex polar lipid APIs.